However, 46 (30.3%) oncologists indicated that their patients were tested for KRAS tumour mutation status only, and the remaining 58 (38.2%) indicated that while some patients were tested for RAS tumour mutation status, some patients had only been tested for KRAS tumour mutation status. Here, KRAS is linked to neoplasm.